Trial · NCT02060721
Adverse events105
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 105
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Systemic Lupus Erythematosus | Musculoskeletal and connective tissue disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Basal Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Breast Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Breast Cancer Metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Gastric Cancer Stage Iv | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Diplegia | Nervous system disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Haemorrhage Intracranial | Nervous system disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Haematuria | Renal and urinary disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Renal Failure | Renal and urinary disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Asthma | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 3 |
| serious | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 2 | 76 | 2 |
| serious | Haemoptysis | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 2 | 76 | 3 |
| serious | Hypercapnia | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Obstructive Airways Disorder | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Pickwickian Syndrome | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 3 | 76 | 3 |
| serious | Pulmonary Hypertension | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 6 | 76 | 6 |
| serious | Sleep Apnoea Syndrome | Respiratory, thoracic and mediastinal disorders | Macitentan 10 Milligrams (mg) | 1 | 76 | 1 |
| serious | Angioplasty | Surgical and medical procedures | Macitentan 10 Milligrams (mg) | 3 | 76 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02060721/events?page=5